Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593473 · ClinicalTrials.gov registry record · Phase 2
Inhaled Oxytocin and HPA Axis Reactivity
A Phase 2 study of Anxiety Disorders and Stress, Psychological, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 1
- Study location
NCT03593473 is a Phase 2 study of Anxiety Disorders and Stress, Psychological that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 109 participants, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03593473, a Phase 2 study of Anxiety Disorders and Stress, Psychological, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 1
- Study location
Study Summary
Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to participate in the 6-year follow-up maternal visit. At the time of this visit, mothers will be randomized to a single 24 IU dose of nasal oxytocin or placebo. Following administration of the study drug, women will participate in the Trier Social Stress Test (TSST), and blood samples will be collected to quantify HPA axis reactivity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Intranasal Oxytocin
Study Locations (1)
North Carolina
- University of North Carolina School of Medicine - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03593473
The ClinicalTrials.gov registry entry for NCT03593473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (90% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03593473 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03593473 about?
NCT03593473 is a clinical study titled "Inhaled Oxytocin and HPA Axis Reactivity". Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to participate in the 6-year follow-up maternal visit. At the time of this visit, mothers will be randomized to a single 24 IU dose of nasal oxytocin or placebo. Following administration of the study drug, women will par...
What is the current status of trial NCT03593473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2019-02-07. Estimated completion is 2023-07-25.
What conditions does trial NCT03593473 study?
This clinical trial studies the following conditions: Anxiety Disorders, Stress, Psychological, Depression, Postpartum.
What interventions are being tested in trial NCT03593473?
The interventions under investigation include: Placebo (DRUG), Intranasal Oxytocin (DRUG).
Who is sponsoring clinical trial NCT03593473?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03593473 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
-
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
RECRUITING · Phase 2
-
Pramipexole to Enhance Social Connections
RECRUITING · Phase 2
-
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 2
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.